Details

Autor(en) / Beteiligte

• Müller, T.D.
• Finan, B.
• Bloom, S.R.
• D'Alessio, D.
• Drucker, D.J.
• Flatt, P.R.
• Fritsche, A.
• Gribble, F.
• Grill, H.J.
• Habener, J.F.
• Holst, J.J.
• Langhans, W.
• Meier, J.J.
• Nauck, M.A.
• Perez-Tilve, D.
• Pocai, A.
• Reimann, F.
• Sandoval, D.A.
• Schwartz, T.W.
• Seeley, R.J.
• Stemmer, K.
• Tang-Christensen, M.
• Woods, S.C.
• DiMarchi, R.D.
• Tschöp, M.H.

Titel

Glucagon-like peptide 1 (GLP-1)

Ist Teil von

• Molecular metabolism (Germany), 2019-12, Vol.30, p.72-130

Ort / Verlag

Germany: Elsevier GmbH

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders